New York Life Investment Management LLC Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

New York Life Investment Management LLC boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,523 shares of the medical equipment provider’s stock after acquiring an additional 257 shares during the period. New York Life Investment Management LLC’s holdings in Hologic were worth $2,752,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in HOLX. Nordea Investment Management AB raised its position in shares of Hologic by 4.5% during the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock valued at $113,077,000 after purchasing an additional 69,494 shares during the period. Louisiana State Employees Retirement System purchased a new position in shares of Hologic in the fourth quarter valued at about $1,057,000. Pathstone Family Office LLC boosted its stake in shares of Hologic by 96.0% in the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after acquiring an additional 4,542 shares during the period. Ontario Teachers Pension Plan Board grew its position in shares of Hologic by 186.7% during the third quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after purchasing an additional 25,010 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its stake in Hologic by 145.3% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 468 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HOLX. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Friday. JPMorgan Chase & Co. raised their target price on shares of Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research note on Friday. Raymond James boosted their price target on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Friday. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and an average target price of $84.56.

Insider Activity

In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Hologic Trading Up 0.8 %

Shares of NASDAQ HOLX opened at $76.54 on Monday. The stock has a market capitalization of $17.97 billion, a P/E ratio of 39.05, a PEG ratio of 2.59 and a beta of 1.01. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $86.74. The business’s 50 day moving average is $76.13 and its two-hundred day moving average is $73.05. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.05. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 18.81% and a net margin of 11.78%. Hologic’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.06 EPS. As a group, research analysts expect that Hologic, Inc. will post 4.08 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.